Back to search results

Equol and Vascular Function in Women With Chronic Kidney Disease

This study is looking at whether a daily supplement called equol can improve blood vessel health in women with chronic kidney disease (CKD) stages 3 or 4. Women with CKD often have problems with their blood vessels, which increases their risk of heart disease. This study will compare equol (10 mg per day) to a placebo (an inactive pill) over 12 weeks. Researchers will measure how well your blood vessels expand (Brachial Artery Flow-Mediated Dilation or FMDBA) to see if equol helps. You may be able to join if you are a postmenopausal woman, aged 50 or older, with CKD stage 3 or 4, and have stable kidney function. The study is currently recruiting 74 participants.

Study design
This is an interventional study comparing equol to a placebo in 74 women. The phase of the study is not specified.
What's involved
You would take two capsules daily for 12 weeks. Your blood vessel function will be measured at the beginning and end of this period.
Compensation
Not stated in the trial record.
Follow-up
Your blood vessel function will be measured at 12 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07194590

Equol and Vascular Function in Women With Chronic Kidney Disease

Recruiting
PHASE2Ages 50+InterventionalTreatment
University of Colorado, Denver
~74 participants
Updated 2026-06-02 on ClinicalTrials.gov
What's tested:EquolPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Brachial Artery Flow-Mediated Dilation (FMDBA)
Measured over Baseline, 12 weeksv

Conditions

Chronic Kidney Disease (Stage 3-4)
Vascular Function
Cognitive Functions
Cerebrovascular Function
Blood Pressure

Explore related trials

Chronic Kidney Disease

NCT07194590

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Colorado Anschutz Medical Campus

    Aurora, Coloradostudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Ester Oh, PhD
[email protected]
303-724-3765
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Postmenopausal women
Aged ≥50 years
CKD stage 3 or 4 (eGFR with the CKD-EPI 2021 race-free equation: 15-59 mL/min/1.73m2; stable renal function in the past 3 months)
Low habitual intake of soy (soy-related food intake \< 2 times per week assessed by Soy-Specific Food Frequency Questionnaire)
Weight stable in the prior 3 months (\<2 kg weight change) and willing to remain weight stable throughout the study
Ability to provide informed consent.

Exclusion

Patients with advanced CKD requiring chronic dialysis
Uncontrolled hypertension in CKD group (BP \>140/90 mmHg)
Use of any hormone replacement therapy
Allergy and/or intolerance to soy or soy-based products
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin values 2X upper limit of normal range (upper limit of normal range AST: 117 U/L; ALT: 52 U/L; total bilirubin: 1.3 mg/dL)
History of breast cancer
Significant co-morbid conditions with a life expectancy of \< 1 year
Current tobacco or nicotine use or history of use in the last 12 months
History of kidney transplant
History of severe congestive heart failure (i.e., ejection fraction \<35%)
History of hospitalization within the last month
Immunosuppressant agents taken in the past 12 months
Known malignancy

What this trial measures

  • Brachial Artery Flow-Mediated Dilation (FMDBA)Baseline, 12 weeksv

    Flow-mediated dilation of the brachial artery will be performed using ultrasonography and analyzed with a commercially available software package as percent change in diameter from baseline following reactive hyperemia.